US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARS PHARMACEUTICALS INC

13.93

-0.6037-4.15%

Volume:453.15K

Turnover:6.46M

Market Cap:1.37B

PE:-86.61

High:14.70

Open:14.50

Low:13.88

Close:14.53

Loading ...

Overview Company News Filings

William Blair Remains a Buy on ARS Pharmaceuticals (SPRY)

Brent L. Saunders, Director, Reports Disposal of Common Shares in ARS Pharmaceuticals Inc

Alexander A. Fitzpatrick, Chief Legal Officer, Reports Disposal of Common Shares of ARS Pharmaceuticals Inc

Raymond James Keeps Their Buy Rating on ARS Pharmaceuticals (SPRY)

Stock Track | ARS Pharmaceuticals Soars 11.57% Following Strong Q1 Results and Positive Outlook

Stock Track | ARS Pharmaceuticals (SPRY) Soars 11.57% as Q1 Results Beat Expectations

Stock Track | ARS Pharmaceuticals Soars 5.79% After-Hours on Strong Q1 Revenue Beat and In-Line EPS

ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss

ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Stock Track | ARS Pharmaceuticals Plunges 6.37% Pre-market on Wider Q1 Loss Despite Revenue Beat

BRIEF-ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million

ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates

MT Newswires Live

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Net Loss $0.35 a Share, vs. FactSet Est of $0.32 Loss

MT Newswires Live

Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-Than-Expected Q1 Results

Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-than-Expected Q1 Results

ARS Pharmaceuticals Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $7.97M Beat $7.48M Estimate

ARS Pharmaceuticals Reports Q1 2025 Results: $7.8M in Neffy Sales, $33.9M Net Loss, EPS at $0.35

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of Neffy® (Epinephrine Nasal Spray)

THOMSON REUTERS

ARS Pharmaceuticals Q1 Basic EPS USD -0.35

THOMSON REUTERS

ARS Pharmaceuticals Q1 Cash & Investments USD 275.7 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SPRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":13.9263,"timestamp":1749063775195,"preClose":14.53,"halted":0,"volume":453148,"delay":0,"floatShares":51755894,"shares":98213561,"eps":-0.160792,"marketStatus":"Trading","change":-0.6037,"latestTime":"06-04 15:03:04 EDT","open":14.5,"high":14.7,"low":13.88,"amount":6462654.940676,"amplitude":0.056435,"askPrice":13.93,"askSize":151,"bidPrice":13.91,"bidSize":524,"shortable":3,"etf":0,"ttmEps":-0.160792,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749067200000},"marketStatusCode":2,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":14.53,"preHourTrading":{"tag":"盘前","latestPrice":14.49,"preClose":14.53,"latestTime":"09:29 EDT","volume":512,"amount":7408.169984,"timestamp":1749043799999},"postHourTrading":{"tag":"盘后","latestPrice":14.53,"preClose":14.53,"latestTime":"19:00 EDT","volume":26092,"amount":379135.52,"timestamp":1748991616143},"volumeRatio":0.411482,"impliedVol":0.1426,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":51755894,"roa":"-6.10%","roe":"-6.91%","lyrEps":0.082507,"volumeRatio":0.411482,"shares":98213561,"dividePrice":0,"high":14.7,"amplitude":0.056435,"preClose":14.53,"low":13.88,"week52Low":7.55,"pbRate":"5.97","psRate":"14.08","week52High":18.51,"institutionHeld":0,"latestPrice":13.9263,"committee":0.552593,"eps":-0.160792,"divideRate":0,"volume":453148,"delay":0,"ttmEps":-0.160792,"open":14.5,"prevYearClose":10.55,"prevWeekClose":14.43,"prevMonthClose":14.43,"prevQuarterClose":12.58,"fiveDayClose":14.85,"twentyDayClose":14.02,"sixtyDayClose":10.83},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540121700","title":"William Blair Remains a Buy on ARS Pharmaceuticals (SPRY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540121700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540121700?lang=en_us&edition=fundamental","pubTime":"2025-06-04 06:15","pubTimestamp":1748988920,"startTime":"0","endTime":"0","summary":"William Blair analyst Lachlan Hanbury Brown reiterated a Buy rating on ARS Pharmaceuticals (SPRY – Research Report) today. The company’s shares clo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-remains-a-buy-on-ars-pharmaceuticals-spry-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-remains-a-buy-on-ars-pharmaceuticals-spry-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2537927282","title":"Brent L. Saunders, Director, Reports Disposal of Common Shares in ARS Pharmaceuticals Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2537927282","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537927282?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:01","pubTimestamp":1747947668,"startTime":"0","endTime":"0","summary":"Brent L. Saunders, a Director at ARS Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL37VsQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2537927453","title":"Alexander A. Fitzpatrick, Chief Legal Officer, Reports Disposal of Common Shares of ARS Pharmaceuticals Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2537927453","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537927453?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:00","pubTimestamp":1747947653,"startTime":"0","endTime":"0","summary":"Alexander A. Fitzpatrick, the Chief Legal Officer of ARS Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL2MMchV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2535882288","title":"Raymond James Keeps Their Buy Rating on ARS Pharmaceuticals (SPRY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535882288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535882288?lang=en_us&edition=fundamental","pubTime":"2025-05-15 22:36","pubTimestamp":1747319786,"startTime":"0","endTime":"0","summary":"In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a price ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/raymond-james-keeps-their-buy-rating-on-ars-pharmaceuticals-spry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/raymond-james-keeps-their-buy-rating-on-ars-pharmaceuticals-spry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","RJF"],"gpt_icon":0},{"id":"1155819446","title":"Stock Track | ARS Pharmaceuticals Soars 11.57% Following Strong Q1 Results and Positive Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1155819446","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155819446?lang=en_us&edition=fundamental","pubTime":"2025-05-15 09:50","pubTimestamp":1747273854,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals Inc  experienced a significant surge, soaring 11.57% on Wednesday, following the release of the company's impressive first-quarter 2025 financial results. The biotechnology and medical research firm's performance exceeded analyst expectations in key areas, sparking investor enthusiasm.Investors were particularly encouraged by ARS Pharmaceuticals' solid cash position, with the company reporting cash and investments of $275.7 million at the end of the quarter. This st","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1130142281","title":"Stock Track | ARS Pharmaceuticals (SPRY) Soars 11.57% as Q1 Results Beat Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1130142281","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130142281?lang=en_us&edition=fundamental","pubTime":"2025-05-15 09:50","pubTimestamp":1747273849,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals Inc  surged 11.57% in a 24-hour period, following the release of the company's first-quarter 2025 financial results that exceeded analyst expectations. The biotechnology and medical research firm's strong performance and positive outlook have fueled investor enthusiasm.ARS Pharmaceuticals reported Q1 revenue of $7.97 million, surpassing the mean analyst estimate of $7.48 million. While the company posted a quarterly adjusted loss of 35 cents per share, it met the co","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1178365579","title":"Stock Track | ARS Pharmaceuticals Soars 5.79% After-Hours on Strong Q1 Revenue Beat and In-Line EPS","url":"https://stock-news.laohu8.com/highlight/detail?id=1178365579","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178365579?lang=en_us&edition=fundamental","pubTime":"2025-05-15 07:10","pubTimestamp":1747264247,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals Inc  surged 5.79% in after-hours trading on Wednesday, following the release of the company's first-quarter 2025 financial results that exceeded analyst expectations in key areas.The biotechnology and medical research firm reported Q1 revenue of $7.97 million, surpassing the mean analyst estimate of $7.48 million. While the company posted a quarterly adjusted loss of 35 cents per share, it met the consensus expectation of six analysts. The reported net loss for the ","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2535008648","title":"ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2535008648","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535008648?lang=en_us&edition=fundamental","pubTime":"2025-05-15 00:51","pubTimestamp":1747241460,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals slipped after the biopharmaceutical company reported a first-quarter loss that was wider than analysts had expected.The stock was down 9%, to $12.12, in midday trading Wednesday, but has gained about 14% since the start of the year.The San Diego company reported a first-quarter loss of $34.1 million, or 35 cents a share. Analysts polled by FactSet were looking for a loss of $31.2 million, or 34 cents a share.Revenue for the quarter was $8 million, compared with the $7.5 million analysts were expecting.Product revenue from its neffy sales in the U.S. were $7.8 million, and $200,000 in revenue came from a collaboration with Denmark's ALK-Abello. Neffy is a nasal spray used for emergency treatment of allergic reactions, including anaphylaxis.ARS said it had cash, cash equivalents and short-term investments of $275.7 million as of March 31.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2535272630","title":"ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535272630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535272630?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:32","pubTimestamp":1747229542,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 35 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nL8N3RM1LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"1194819562","title":"Stock Track | ARS Pharmaceuticals Plunges 6.37% Pre-market on Wider Q1 Loss Despite Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1194819562","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194819562?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:02","pubTimestamp":1747224156,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock price plummet 6.37% in pre-market trading following the release of its first-quarter 2025 financial results. The company reported a wider-than-expected loss, overshadowing its revenue beat and progress in the commercial launch of its flagship product, Neffy .Despite the revenue beat, investors seem concerned about the company's rising expenses. ARS Pharmaceuticals reported operating expenses of $45.15 million, with selling, general, and administrative expen","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2535025812","title":"BRIEF-ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025812","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025812?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:53","pubTimestamp":1747223627,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million May 14 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS Q1 OPERATING INCOME USD -37.177 MILLION VERSUS. IBES ESTIMATE US","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nPLX4A87C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2535402570","title":"ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535402570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535402570?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:26","pubTimestamp":1747221991,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  reported a Q1 net loss Wednesday of $0.35 per diluted share, wider than a loss of $0.11 a year earlier.Analysts polled by FactSet expected a loss of $0.32.Revenue for the quarter ended March 31 was $8 million.Analysts surveyed by FactSet expected $7.5 million.As of March 31, the company said it had $275.7 million in cash and cash equivalents on hand, and expected it could fund operations through the next three years.ARS' shares were 1.1% higher in premarket trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY"],"gpt_icon":0},{"id":"2535047161","title":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Net Loss $0.35 a Share, vs. FactSet Est of $0.32 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2535047161","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535047161?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:12","pubTimestamp":1747221125,"startTime":"0","endTime":"0","summary":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Net Loss $0.35 a Share, vs. FactSet Est of $0.32 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY"],"gpt_icon":0},{"id":"1187880914","title":"Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-Than-Expected Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1187880914","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187880914?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:02","pubTimestamp":1747220544,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals Inc  are surging in pre-market trading on Wednesday, up 8.31% following the release of the company's first-quarter financial results. The pharmaceutical firm's stock is attracting investor attention as it outperformed analyst expectations in its latest earnings report.ARS Pharmaceuticals reported a net loss of $33.94 million for the first quarter, which was notably better than the consensus estimate of a $34.6 million loss projected by analysts polled by IBES. This ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1144452584","title":"Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-than-Expected Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1144452584","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144452584?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:02","pubTimestamp":1747220540,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals Inc  surged 8.31% in pre-market trading on Wednesday, following the release of its first-quarter financial results. The pharmaceutical company's performance exceeded analysts' expectations, sparking investor optimism.ARS Pharmaceuticals reported a net loss of $33.94 million for the first quarter, which was better than the IBES estimate of a $34.6 million loss. This narrower-than-expected loss suggests that the company is managing its finances more efficiently than a","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-than-Expected Q1 Results","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2535468042","title":"ARS Pharmaceuticals Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $7.97M Beat $7.48M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535468042","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535468042?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:01","pubTimestamp":1747220518,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 6.06 percent. This is a 218.18 percent decrease over losses of $(0.11) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45402287/ars-pharmaceuticals-q1-eps-0-35-misses-0-33-estimate-sales-7-97m-beat-7-48m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2535042271","title":"ARS Pharmaceuticals Reports Q1 2025 Results: $7.8M in Neffy Sales, $33.9M Net Loss, EPS at $0.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042271","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042271?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220423,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. reported its financial results for the first quarter of 2025, highlighting total revenues of $8.0 million. This figure includes $7.8 million in net product revenue from sales of **_neffy_** in the U.S. and $0.2 million in collaboration revenue from ALK-Abelló A/S . The company reported a net loss of $33.9 million for the quarter. Research and development expenses amounted to $3.0 million, primarily associated with the ongoing clinical and development efforts for **_neffy_**. Selling, general, and administrative expenses were $41.1 million, largely due to personnel-related and sales and marketing expenses tied to the commercialization of **_neffy_**. ARS Pharmaceuticals also provided an update on the U.S. commercial launch of **_neffy_** , the first FDA-approved and European Commission-approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis. The product has been prescribed by over 5,000 physicians, demonstrating considerab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL3D7KKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","NDAQ"],"gpt_icon":0},{"id":"2535104292","title":"ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of Neffy® (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535104292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535104292?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA47TQ3H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2535967042","title":"ARS Pharmaceuticals Q1 Basic EPS USD -0.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2535967042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535967042?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nPLX4A87C3:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2535042924","title":"ARS Pharmaceuticals Q1 Cash & Investments USD 275.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042924?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nPLX4A87C3:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":111,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"SPRY","fiscalQuarterEnding":"2025/03","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52},{"market":"US","date":"2025-01-13","symbol":"SPRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1736744400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"SPRY","fiscalQuarterEnding":"2024/09","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-08-06","symbol":"SPRY","fiscalQuarterEnding":"2024/06","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"post","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1741320000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2025-06-03","current":-90.745565,"percent":0.009693,"low":-97.209461,"twenty":-28.80529,"median":-17.721638,"eighty":-11.147184,"high":184.020638,"avg":-10.287664,"sd":47.265661,"marketCap":1420168092},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.313866,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":860429873},{"date":"2024-06-07","current":-17.177383,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":853647205},{"date":"2024-06-14","current":-16.884919,"twenty":-27.543213,"median":-15.872834,"eighty":-9.957071,"marketCap":839112916},{"date":"2024-06-21","current":-15.929536,"twenty":-27.026227,"median":-15.872834,"eighty":-9.981995,"marketCap":791634241},{"date":"2024-06-28","current":-16.592455,"twenty":-26.233342,"median":-15.857321,"eighty":-10.038073,"marketCap":824578628},{"date":"2024-07-05","current":-17.742813,"twenty":-26.122559,"median":-15.901185,"eighty":-10.097267,"marketCap":881746829},{"date":"2024-07-12","current":-22.129772,"twenty":-26.004391,"median":-15.977907,"eighty":-10.112844,"marketCap":1099761155},{"date":"2024-07-19","current":-20.550467,"twenty":-25.84191,"median":-16.008119,"eighty":-10.131537,"marketCap":1021275998},{"date":"2024-07-26","current":-21.408361,"twenty":-25.598187,"median":-16.06602,"eighty":-10.234348,"marketCap":1063909910},{"date":"2024-08-02","current":-19.302621,"twenty":-25.251068,"median":-16.155521,"eighty":-10.620668,"marketCap":959263034},{"date":"2024-08-09","current":-23.520911,"twenty":-24.881793,"median":-16.206368,"eighty":-10.941562,"marketCap":1054724705},{"date":"2024-08-16","current":-28.81744,"twenty":-25.84191,"median":-16.286222,"eighty":-11.035026,"marketCap":1292231647},{"date":"2024-08-23","current":-28.017556,"twenty":-27.270827,"median":-16.393243,"eighty":-11.081758,"marketCap":1256363252},{"date":"2024-08-30","current":-28.060793,"twenty":-27.941591,"median":-16.401625,"eighty":-11.197031,"marketCap":1258302084},{"date":"2024-09-06","current":-24.558599,"twenty":-27.79336,"median":-16.442915,"eighty":-11.309188,"marketCap":1101256678},{"date":"2024-09-13","current":-28.752585,"twenty":-27.79336,"median":-16.472628,"eighty":-11.620736,"marketCap":1289323399},{"date":"2024-09-20","current":-31.930502,"twenty":-27.995938,"median":-16.576918,"eighty":-11.620736,"marketCap":1431827564},{"date":"2024-09-27","current":-30.95767,"twenty":-28.060793,"median":-16.631178,"eighty":-11.714201,"marketCap":1388203840},{"date":"2024-10-04","current":-30.67663,"twenty":-28.212122,"median":-16.751589,"eighty":-11.833393,"marketCap":1375601431},{"date":"2024-10-11","current":-31.39004,"twenty":-28.39555,"median":-16.860498,"eighty":-11.83882,"marketCap":1407592162},{"date":"2024-10-18","current":-34.567957,"twenty":-28.752585,"median":-16.884919,"eighty":-11.967761,"marketCap":1550096327},{"date":"2024-10-25","current":-31.930502,"twenty":-28.968769,"median":-17.021402,"eighty":-12.05734,"marketCap":1431827564},{"date":"2024-11-01","current":-32.989808,"twenty":-29.172776,"median":-17.10772,"eighty":-12.236498,"marketCap":1479328953},{"date":"2024-11-08","current":-36.837898,"twenty":-29.53085,"median":-17.177383,"eighty":-12.27233,"marketCap":1651885017},{"date":"2024-11-15","current":-27.728261,"twenty":-29.574087,"median":-17.203935,"eighty":-12.290246,"marketCap":1361568504},{"date":"2024-11-22","current":-27.708469,"twenty":-29.53085,"median":-17.216378,"eighty":-12.329028,"marketCap":1360596650},{"date":"2024-11-29","current":-28.717849,"twenty":-29.510269,"median":-17.294264,"eighty":-12.329028,"marketCap":1410161242},{"date":"2024-12-06","current":-27.748052,"twenty":-29.318167,"median":-17.323614,"eighty":-12.355333,"marketCap":1362540359},{"date":"2024-12-13","current":-23.552198,"twenty":-29.200708,"median":-17.377363,"eighty":-12.390575,"marketCap":1156507152},{"date":"2024-12-20","current":-22.127191,"twenty":-29.174826,"median":-17.429503,"eighty":-12.426406,"marketCap":1086533610},{"date":"2024-12-27","current":-21.355313,"twenty":-29.123341,"median":-17.460097,"eighty":-12.465821,"marketCap":1048631275},{"date":"2025-01-03","current":-22.146983,"twenty":-29.064257,"median":-17.508842,"eighty":-12.501652,"marketCap":1087505465},{"date":"2025-01-10","current":-22.245942,"twenty":-29.025066,"median":-17.556082,"eighty":-12.530317,"marketCap":1092364739},{"date":"2025-01-17","current":-24.878247,"twenty":-29.013807,"median":-17.625827,"eighty":-12.566149,"marketCap":1221621420},{"date":"2025-01-24","current":-27.866803,"twenty":-28.968769,"median":-17.665522,"eighty":-12.594815,"marketCap":1368371488},{"date":"2025-01-31","current":-25.768876,"twenty":-28.968769,"median":-17.692748,"eighty":-12.61273,"marketCap":1265354884},{"date":"2025-02-07","current":-23.591782,"twenty":-28.81744,"median":-17.719962,"eighty":-12.684394,"marketCap":1158450862},{"date":"2025-02-14","current":-23.7897,"twenty":-28.81245,"median":-17.725862,"eighty":-12.70231,"marketCap":1168169409},{"date":"2025-02-21","current":-22.245942,"twenty":-28.80529,"median":-17.742813,"eighty":-12.730975,"marketCap":1092364739},{"date":"2025-02-28","current":-20.741768,"twenty":-28.766646,"median":-17.750677,"eighty":-12.878556,"marketCap":1018503778},{"date":"2025-03-07","current":-21.474063,"twenty":-28.753554,"median":-17.783612,"eighty":-12.988431,"marketCap":1054462403},{"date":"2025-03-14","current":-23.492823,"twenty":-28.724796,"median":-17.918291,"eighty":-13.032048,"marketCap":1153591588},{"date":"2025-03-21","current":151.633005,"twenty":-28.645299,"median":-17.929848,"eighty":-12.988431,"marketCap":1212760777},{"date":"2025-03-28","current":153.227851,"twenty":-28.604711,"median":-17.78435,"eighty":-12.670061,"marketCap":1225516351},{"date":"2025-04-04","current":157.030944,"twenty":-28.551598,"median":-17.756493,"eighty":-12.515985,"marketCap":1255933491},{"date":"2025-04-11","current":172.365997,"twenty":-28.537065,"median":-17.742813,"eighty":-12.355333,"marketCap":1378583246},{"date":"2025-04-17","current":182.548472,"twenty":-28.53527,"median":-17.728408,"eighty":-12.28308,"marketCap":1460022683},{"date":"2025-04-25","current":168.930945,"twenty":-28.478265,"median":-17.719962,"eighty":-11.916185,"marketCap":1351109701},{"date":"2025-05-02","current":177.55989,"twenty":-28.413636,"median":-17.701176,"eighty":-11.620736,"marketCap":1420124003},{"date":"2025-05-09","current":165.034919,"twenty":-28.363303,"median":-17.672598,"eighty":-11.047488,"marketCap":1319949281},{"date":"2025-05-16","current":-85.348526,"twenty":-28.478265,"median":-17.679674,"eighty":-10.985179,"marketCap":1335704429},{"date":"2025-05-23","current":-91.122103,"twenty":-28.610323,"median":-17.701176,"eighty":-11.047488,"marketCap":1426060905},{"date":"2025-05-30","current":-97.209461,"twenty":-28.755493,"median":-17.719962,"eighty":-11.103567,"marketCap":1521328059},{"date":"2025-06-03","current":-90.745565,"twenty":-28.80529,"median":-17.721638,"eighty":-11.147184,"marketCap":1420168092}],"updateTime":1749034701913}}}